2,507 results on '"Vannucchi, Alessandro M"'
Search Results
2. Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis
3. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
4. Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study
5. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience
6. CALR mutations possess unique prognostic relevance in myelofibrosis—before and after transplant
7. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis
8. Myeloid sarcoma: more and less than a distinct entity
9. Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion
10. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
11. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group
12. The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients
13. Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
14. International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
15. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
16. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
17. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
18. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
19. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
20. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
21. Anemia in myelofibrosis: Current and emerging treatment options
22. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
23. Site‐specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival
24. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
25. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5
26. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
27. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives
28. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
29. Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports.
30. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
31. Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis
32. Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data
33. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
34. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial
35. Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.
36. Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
37. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
38. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study
39. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
40. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
41. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
42. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
43. Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis
44. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features
45. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
46. How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey
47. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study
48. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients
49. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
50. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.